The increasing availability of DNA-based diagnostic tests has raised issues about whether these should be applied to the population at large in order to identify, treat or prevent a range of diseases. DNA tests raise concerns in the community for several reasons. There is the possibility of stigmatisation and discrimination between those who test positive and those who don't. High-risk individuals may be identified for whom no proven effective intervention is possible, or conversely may test "positive" for a disease that does not eventuate. Controversy concerning prenatal diagnosis and termination of affected pregnancies may arise. Haemochromatosis, however, is a disease that is not only treatable but also preventable if those at high risk are identified presymptomatically. This paper will identify and discuss key issues regarding DNA-based population screening for haemochromatosis, and argue that population-based genetic screening for haemochromatosis should be supported when a number of contentious issues are addressed. In the context of a health system with limited resources haemochromatosis is the paradigm of a disorder where there is an ethical and clinical imperative to encourage presymptomatic DNA testing for all in ethnically relevant communities.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Other content recommended for you
- The challenge of integrating genetic medicine into primary care
- Reverse cascade screening of newborns for hereditary haemochromatosis: a model for other late onset diseases?
- Audit of prenatal diagnosis for haemoglobin disorders in the United Kingdom: the first 20 years
- Population screening for haemochromatosis
- Genetic testing and reproductive choice in neurological disorders
- Genetic information but not termination: pregnant women's attitudes and willingness to pay for carrier screening for deafness genes
- Genetic testing for haemochromatosis in patients with chondrocalcinosis
- Expanding insurance coverage for in vitro fertilisation with preimplantation genetic testing: putting the cart before the horse
- Hostile environments? Down’s syndrome and genetic screening in contemporary culture
- Informed choice in genetic screening for thalassaemia during pregnancy: audit from a national confidential inquiry